Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Recurrence 2Polycystic Ovary Syndrome 2Pleural Effusion, Malignant 2Neoplasms 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Triple Negative Breast Neoplasms 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 25Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × Pharmaceutical Preparations × Clear all
NCT01544322 2015-06-18

ME-344-001

MEI Pharma, Inc.

Phase 1 Completed
24 enrolled

Neoplasm Metastasis, Recurrence

NCT01401868 2013-06-24

Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors

MEI Pharma, Inc.

Phase 1 Completed
18 enrolled

Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡